

# Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

## CAL-85-1

RRID:CVCL\_1114

Type: Cell Line

### Proper Citation

RRID:CVCL\_1114

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1114](https://web.expasy.org/cellosaurus/CVCL_1114)

**Proper Citation:** RRID:CVCL\_1114

**Description:** Cell line CAL-85-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Breast carcinoma

**Defining Citation:** [PMID:7531416](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

**Comments:** Population: Asian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** CAL-85-1

**Synonyms:** Cal-85-1, CAL 85-1, CAL85-1, CAL851, Centre Antoine Lacassagne-85-1

**Cross References:** CLO:CLO\_0002190, EFO:EFO\_0005359, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473094, BioSample:SAMN10988345, cancercellines:CVCL\_1114, Cell\_Model\_Passport:SIDM00928, ChEMBL-Cells:ChEMBL3308700, ChEMBL-Targets:ChEMBL1075415, Cosmic:910852, Cosmic:2164987, Cosmic-CLP:910852, DepMap:ACH-000857, DSMZ:ACC-440, DSMZCellDive:ACC-440, EGA:EGAS00001000610, EGA:EGAS00001000978,

EGA:EGAS00001002554, GDSC:910852, GEO:GSM274639, GEO:GSM344363, GEO:GSM344413, GEO:GSM827163, GEO:GSM843484, GEO:GSM843485, GEO:GSM847247, GEO:GSM847457, GEO:GSM886913, GEO:GSM887979, GEO:GSM1172947, GEO:GSM1669657, IARC\_TP53:21215, LiGeA:CCLE\_496, LINCS\_HMS:51112, LINCS\_LDP:LCL-1465, Lonza:1212, PharmacDB:CAL851\_177\_2019, Progenetix:CVCL\_1114, PubChem\_Cell\_line:CVCL\_1114, Wikidata:Q54808414

**ID:** CVCL\_1114

**Record Creation Time:** 20220427T215439+0000

**Record Last Update:** 20260920T001726+0000

---

## Ratings and Alerts

No rating or validation information has been found for CAL-85-1.

No alerts have been found for CAL-85-1.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. Cancer research communications, 5(3), 458.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer research communications, 5(2), 375.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. Cell reports, 43(8), 114622.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell systems, 12(5), 401.

Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell chemical biology, 27(10), 1229.

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.

Hafner M, et al. (2019) Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. *Cell chemical biology*, 26(8), 1067.